Back to Insider Trading View Full Company Profile

ZYME

UNKNOWN

Zymeworks Inc.

CIK: 0001937653

Strong Sell (90% confidence)

Last activity: Jan 12, 2026

Financial Metrics

As of Dec 31, 2024 (10-K)

Revenue $412.48M
Net Income -$122.69M

Insider Roster (4 total, 4 active)

Insider Buys Sells Net Value Holdings
Galbraith Kenneth
Chair & CEO
0 4 -$3.34M
226,842 shares
$5.14M
Moore Paul Andrew
Chief Scientific Officer
0 3 -$721K
48,497 shares
$1.10M
Smith Jeffrey T L
EVP & Chief Medical Officer
0 2 -$476K
26,708 shares
$606K
Hollywood Mark
EVP & Chief Operating Officer
0 1 -$139K
132,913 shares
$3.01M

Recent Transactions

SELL Galbraith Kenneth (Chair & CEO)

30,424 shares @ $22.67

$690K

Jan 12, 2026

Conviction: | View SEC Filing →
SELL Moore Paul Andrew (Chief Scientific Officer)

9,560 shares @ $22.67

$217K

Jan 12, 2026

Conviction: | View SEC Filing →
SELL Smith Jeffrey T L (EVP & Chief Medical Officer)

9,310 shares @ $22.67

$211K

Jan 12, 2026

Conviction: | View SEC Filing →
SELL Hollywood Mark (EVP & Chief Operating Officer)

6,120 shares @ $22.67

$139K

Jan 12, 2026

Conviction: | View SEC Filing →
SELL Galbraith Kenneth (Chair & CEO)

31,686 shares @ $25.10

$795K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Galbraith Kenneth (Chair & CEO)

22,657 shares @ $25.10

$569K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Moore Paul Andrew (Chief Scientific Officer)

10,821 shares @ $25.10

$272K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Smith Jeffrey T L (EVP & Chief Medical Officer)

10,538 shares @ $25.10

$264K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Moore Paul Andrew (Chief Scientific Officer)

9,289 shares @ $25.10

$233K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL Galbraith Kenneth (Chair & CEO)

47,528 shares @ $27.02

$1.28M

Dec 22, 2025

Conviction: | View SEC Filing →

⚠️ Important Disclaimer

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.